Indivior (United States)

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Barbara R. Haight, Susan M. Learned, Céline M. Laffont et al. · The Lancet · 2019 · 268 citations

Opioid Epidemic, Substance Use, Psychiatry +7

Understanding the use of diverted buprenorphine

Theodore J. Cicero, Matthew S. Ellis, Howard D. Chilcoat · Drug and Alcohol Dependence · 2018 · 107 citations · Full text

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

Naoko Ronquest, Tina M. Willson, Leslie Montejano et al. · Substance Abuse and Rehabilitation · 2018 · 100 citations · Full text

Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies

Lucia Carboni, Dennis J. McCarthy, Bruno Delafont et al. · Translational Psychiatry · 2019 · 76 citations · Full text

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

Azmi Nasser, Mark K. Greenwald, Bradley Vince et al. · Journal of Clinical Psychopharmacology · 2015 · 74 citations · Full text